Related news from
Thu, 02 May 2024 11:30:00 +0000	Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the investigational new drug (IND) application for the use of bremelanotide, a melanocortin receptor 4 agonist (MCR4), for the treatment of obesity. The Company is cleared to begin enrollment in a Phase 2
Tue, 30 Apr 2024 11:30:00 +0000	Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here.
Sun, 14 Apr 2024 19:00:28 +0000	10 Micro-Cap Healthcare Stocks Insiders Are Buying In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
Tue, 09 Apr 2024 12:59:00 +0000	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
Mon, 08 Apr 2024 16:02:37 +0000	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated
Mon, 08 Apr 2024 11:30:00 +0000	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
Wed, 28 Feb 2024 12:30:00 +0000	Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
Fri, 16 Feb 2024 15:00:57 +0000	Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.43. Palatin Technologies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome […]
Fri, 16 Feb 2024 05:55:15 +0000	Q2 2024 Palatin Technologies Inc Earnings Call Q2 2024 Palatin Technologies Inc Earnings Call
Thu, 15 Feb 2024 12:30:00 +0000	Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2023.
Fri, 09 Feb 2024 12:30:00 +0000	Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.
Mon, 05 Feb 2024 12:30:00 +0000	Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
Thu, 01 Feb 2024 21:00:00 +0000	Palatin Announces Closing of $10 Million Registered Direct Offering Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock. Palatin has also issued in a private placement warrants to purchase up to an aggregate of 1,831
Tue, 30 Jan 2024 13:00:00 +0000	Palatin Announces $10 Million Registered Direct Offering Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock. Palatin has also agreed
Mon, 29 Jan 2024 10:09:00 +0000	Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength? Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Thu, 11 Jan 2024 18:38:51 +0000	3 Penny Stocks to Buy to Unlock 2,500% Upside Potential After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosens, we could see significant tailwinds for beaten-down penny stocks primed for a rebound. Penny stocks tend to thrive when monetary policies favor economic expansion and easy money. However, the past few years have been the exact opposite, with quantitative tightening, balance sheet contraction, and restric
Mon, 08 Jan 2024 15:33:00 +0000	Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today provided a corporate update, highlighted the Company's key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones.
Wed, 03 Jan 2024 13:00:00 +0000	Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. BRIDGEWATER, N.J., January 03, 2024--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Sat, 23 Dec 2023 22:00:00 +0000	Analysts Say 3 Stocks Have a Combined Upside of 3000% Wall Street analysts can get a bit optimistic with their price targets. So when I see calls for triple-digit upside, I take them with a grain of salt. But the three stocks I’m profiling today have targets so high I had to do a double-take. Analysts forecast these stocks to soar around 2,800% from current levels if their ambitious projections materialize. Now, such returns are obviously on the highest end of probabilities – a lot would need to go right. However, analysts arrive at these targets f
Wed, 20 Dec 2023 12:30:00 +0000	Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million. Vyleesi is the first and only as-needed tr